Health
Drug Compound Targets Weakness in Advanced Prostate Cancer – Technology Networks
A new study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted using the compound thymoquinone.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patient…
-
Noosa News17 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General15 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
General16 hours agoSingapore’s world-first sustainable flights tax will see some Australians pay more to travel
-
General11 hours agoPerth man charged after investigation into organised crime and tobacco store attacks